Skip to main content
SpringerLink
Log in

Saxagliptin: A Review in Type 2 Diabetes

  • Adis Drug Evaluation
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Saxagliptin (Onglyza®) is a highly potent, reversible, competitive dipeptidyl peptidase-4 inhibitor indicated for the treatment of patients with type 2 diabetes. Numerous well-designed clinical studies and their extensions showed that saxagliptin as monotherapy or as dual or triple combination therapy with other antihyperglycaemics improved glycaemic control and was generally well tolerated in patients with type 2 diabetes during ≤2 years’ therapy. Saxagliptin was generally weight-neutral and had a low risk of hypoglycaemia (unless coadministered with agents that may be associated with hypoglycaemia, such as sulfonylureas or insulin). In addition, at a median follow-up of 2.1 years in the large SAVOR-TIMI 53 study, with the exception of a 27 % greater risk of hospitalization for heart failure, the addition of saxagliptin to standard of care neither reduced nor increased the rate of ischemic cardiovascular events in at-risk patients. Although further long-term data will be beneficial, current evidence indicates that saxagliptin is a useful option for the treatment of patients with type 2 diabetes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. World Health Organization. Diabetes: fact sheet No 312. 2015. http://www.who.int/. Accessed 26 Aug 2015.

  2. Neumiller JJ. Incretin pharmacology: a review of the incretin effect and current incretin-based therapies. Cardiovasc Hematol Agents Med Chem. 2012;10(4):276–88.

    Article  CAS  PubMed  Google Scholar 

  3. Omar B, Ahren B. Pleiotropic mechanisms for the glucose-lowering action of DPP-4 inhibitors. Diabetes. 2014;63(7):2196–202.

    Article  PubMed  Google Scholar 

  4. US Food and Drug Administration. Onglyza (saxagliptin): US prescribing information. 2013. http://www.accessdata.fda.gov/. Accessed 26 Aug 2015.

  5. European Medicines Agency. Onglyza (saxagliptin): summary of product characteristics. 2015. http://www.ema.europa.eu/. Accessed 26 Aug 2015.

  6. Yang LP. Saxagliptin: a review of its use as combination therapy in the management of type 2 diabetes mellitus in the EU. Drugs. 2012;72(2):229–48.

    Article  CAS  PubMed  Google Scholar 

  7. Wang A, Dorso C, Kopcho L, et al. Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor. BMC Pharmacol. 2012;12:2.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Tatosian DA, Guo Y, Schaeffer AK, et al. Dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes treated with saxagliptin, sitagliptin, or vildagliptin. Diabetes Therapy. 2013;4(2):431–42.

    Article  PubMed Central  PubMed  Google Scholar 

  9. Barrett YC, Perl S, Ghannam A, et al. Impact of saxagliptin treatment on glycemic biomarkers and β-cell function in patients with T2D [abstract no. 1264-P]. Diabetes. 2015;64(Suppl 1):A328.

    Google Scholar 

  10. Allen E, Cook W, Bryzinski B, et al. Saxagliptin (SAXA) reduces postprandial glucose (PPG) in patients with type 2 diabetes mellitus (T2DM) [abstract no. 2615-PO]. Diabetes. 2013;62(Suppl 1):A665.

    Google Scholar 

  11. Rosenstock J, Aguilar-Salinas C, Klein E, et al. Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes. Curr Med Res Opin. 2009;25(10):2401–11.

    Article  CAS  PubMed  Google Scholar 

  12. DeFronzo RA, Hissa MN, Garber AJ, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care. 2009;32(9):1649–55.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Chacra AR, Tan GH, Apanovitch A, et al. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract. 2009;63(9):1395–406.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  14. Hollander P, Li J, Allen E, et al. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab. 2009;94(12):4810–9.

    Article  CAS  PubMed  Google Scholar 

  15. Leibowitz G, Cahn A, Bhatt DL, et al. Impact of treatment with saxagliptin on glycaemic stability and beta-cell function in the SAVOR-TIMI 53 study. Diabetes Obes Metab. 2015;17(5):487–94.

    Article  CAS  PubMed  Google Scholar 

  16. Jadzinsky M, Pfützner A, Paz-Pacheco E, et al. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab. 2009;11(6):611–22.

    Article  CAS  PubMed  Google Scholar 

  17. Pfützner A, Paz-Pacheco E, Allen E, et al. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes Obes Metab. 2011;13(6):567–76.

    Article  PubMed  Google Scholar 

  18. Göke B, Gallwitz B, Eriksson J, et al. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial. Int J Clin Pract. 2010;64(12):1619–31.

    Article  PubMed  Google Scholar 

  19. Göke B, Gallwitz B, Eriksson JG, et al. Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial. Int J Clin Pract. 2013;67(4):307–16.

    Article  PubMed  Google Scholar 

  20. Scheen AJ, Charpentier G, Östgren CJ, et al. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes Metab Res Rev. 2010;26(7):540–9.

    Article  CAS  PubMed  Google Scholar 

  21. Chacra AR, Tan GH, Ravichandran S, et al. Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks. Diab Vasc Dis Res. 2011;8(2):150–9.

    Article  PubMed  Google Scholar 

  22. Hollander PL, Jia L, Frederich R, et al. Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus. Diab Vasc Dis Res. 2011;8(2):125–35.

    Article  PubMed  Google Scholar 

  23. Moses RG, Kalra S, Brook D, et al. A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea. Diabetes Obes Metab. 2014;16(5):443–50.

    Article  CAS  PubMed  Google Scholar 

  24. Barnett AH, Charbonnel B, Donovan M, et al. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. Curr Med Res Opin. 2012;28(4):513–23.

    Article  CAS  PubMed  Google Scholar 

  25. Barnett AH, Charbonnel B, Li J, et al. Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy. Clin Drug Investig. 2013;33(10):707–17.

    Article  CAS  PubMed  Google Scholar 

  26. Frederich R, McNeill R, Berglind N, et al. The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naive patients with type 2 diabetes mellitus: a randomized controlled trial. Diabetol Metab Syndr. 2012;4(1):36.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  27. Pan CY, Yang W, Tou C, et al. Efficacy and safety of saxagliptin in drug-naïve Asian patients with type 2 diabetes mellitus: a randomized controlled trial. Diabetes Metab Res Rev. 2012;28(3):268–75.

    Article  CAS  PubMed  Google Scholar 

  28. Kumar KMP, Jain SM, Tou C, et al. Saxagliptin as initial therapy in treatment-naive Indian adults with type 2 diabetes mellitus inadequately controlled with diet and exercise alone: a randomized, double-blind, placebo-controlled, phase IIIb clinical study. Int J Diabetes Dev Ctries. 2014;34(4):201–9.

    Article  CAS  Google Scholar 

  29. Fonseca V, Zhu T, Karyekar C, et al. Adding saxagliptin to extended-release metformin vs. uptitrating metformin dosage. Diabetes Obes Metab. 2012;14(4):365–71.

    Article  CAS  PubMed  Google Scholar 

  30. Hermans MP, Delibasi T, Farmer I, et al. Effects of saxagliptin added to sub-maximal doses of metformin compared with uptitration of metformin in type 2 diabetes: the PROMPT study. Curr Med Res Opin. 2012;28(10):1635–45.

    Article  CAS  PubMed  Google Scholar 

  31. Nowicki M, Rychlik I, Haller H, et al. Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment. Diabetes Obes Metab. 2011;13(6):523–32.

    Article  CAS  PubMed  Google Scholar 

  32. Nowicki M, Rychlik I, Haller H, et al. Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study. Int J Clin Pract. 2011;65(12):1230–9.

    Article  CAS  PubMed  Google Scholar 

  33. Schernthaner G, Duran-Garcia S, Hanefeld M, et al. Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION). Diabetes Obes Metab. 2015;17(7):630–8.

    Article  CAS  PubMed  Google Scholar 

  34. Li CJ, Liu XJ, Bai L, et al. Efficacy and safety of vildagliptin, saxagliptin or sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents. Diabetol Metab Syndr. 2014;6:69.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  35. Li CJ, Yu Q, Yu P, et al. Efficacy and safety comparison of add-on therapy with liraglutide, saxagliptin and vildagliptin, all in combination with current conventional oral hypoglycemic agents therapy in poorly controlled Chinese type 2 diabetes. Exp Clin Endocrinol Diabetes. 2014;122(8):469–76.

    Article  CAS  PubMed  Google Scholar 

  36. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–26.

    Article  CAS  PubMed  Google Scholar 

  37. US Food and Drug Administration. Guidance for industry: Diabetes mellitus - evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. 2008. http://www.fda.gov/. Accessed 26 Aug 2015.

  38. Scirica BM, Bhatt DL, Braunwald E, et al. The design and rationale of the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus–Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 Study. Am Heart J. 2011;162(5):818–25.e6.

  39. AstraZeneca. New hypoglycemia and pancreatitis subanalyses from the Onglyza® (saxagliptin) SAVOR cardiovascular outcomes trial presented at the 49th annual meeting of the European Association for the Study of Diabetes (EASD) [media release]. 26 Sep 2013. http://www.astrazeneca.com/.

  40. Mosenzon O, Bhatt DL, Litwak LE, et al. Effect of saxagliptin on renal outcome [abstract no. 183]. Diabetologia. 2014;57(Suppl 1):S84.

    Google Scholar 

  41. Briggs AH, Bhatt DL, Scirica BM, et al. Health-related quality-of-life (HRQoL) implications of cardiovascular events in type 2 diabetes mellitus (T2DM) [abstract no. 2606-PO]. Diabetes. 2015;64(Suppl 1):A659.

    Google Scholar 

  42. Davidson JA. Tolerability of saxagliptin in patients with inadequately controlled type 2 diabetes: results from 6 phase III studies. J Manag Care Pharm. 2014;20(2):120–9.

    PubMed  Google Scholar 

  43. Hirshberg B, Parker A, Edelberg H, et al. Safety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitus. Diabetes Metab Res Rev. 2014;30(7):556–69.

    Article  CAS  PubMed  Google Scholar 

  44. Iqbal N, Allen E, Ohman P. Long-term safety and tolerability of saxagliptin add-on therapy in older patients (aged ≥65 years) with type 2 diabetes. Clin Interv Aging. 2014;9:1479–87.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  45. Mosenzon O, Raz I, Scirica BM, et al. Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trial. Diabetes Metab Res Rev. 2013;29(5):417–26.

    Article  CAS  PubMed  Google Scholar 

  46. Leiter LA, Teoh H, Braunwald E, et al. Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 Trial. Diabetes Care. 2015;38(6):1145–53.

    Article  CAS  PubMed  Google Scholar 

  47. Udell JA, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial. Diabetes Care. 2015;38(4):696–705.

    CAS  PubMed  Google Scholar 

  48. Osei K, Scirica BM, Bhatt DL, et al. Cardiovascular outcomes of saxagliptin treatment in African Americans with type 2 diabetes: results from the SAVOR-TIMI 53 trial [abstract no. 15LB]. In: American Diabetes Association’s 75th scientific sessions. 2015.

  49. Scirica BM, Braunwald E, Raz I, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014;130(18):1579–88.

    Article  CAS  PubMed  Google Scholar 

  50. Cahn A, Mosenzon O, Hirshberg B, et al. Risk of cardiovascular events with the use of sulfonylureas: post hoc analysis from the SAVOR trial [abstract no. 504-P]. Diabetes. 2015;64(Suppl 1):A130.

    Google Scholar 

  51. Raz I, Cahn A, Scirica BM, et al. Predisposing factors for hypoglycaemia: analysis from the SAVOR-TIMI 53 trial [abstract no. 641]. Diabetologia. 2014;57(Suppl 1):S263.

    Google Scholar 

  52. Raz I, Bhatt DL, Hirshberg B, et al. Incidence of pancreatitis and pancreatic cancer in a randomized controlled multicenter trial (SAVOR-TIMI 53) of the dipeptidyl peptidase-4 inhibitor saxagliptin. Diabetes Care. 2014;37(9):2435–41.

    Article  CAS  PubMed  Google Scholar 

  53. Raz I, Cahn A, Eliaschewitz FG, et al. Saxagliptin effect on liver enzymes in the SAVOR trial [abstract no. 1227-P]. Diabetes. 2015;64(Suppl 1):A317.

    Google Scholar 

  54. Leiter LA, Teoh H, Mosenzon O, et al. Saxagliptin and cancer in the SAVOR-TIMI 53 Trial [abstract no. 11-OR plus oral presentation]. Diabetes. 2015;64(Suppl 1):A3.

    Google Scholar 

  55. Cahn A, Mosenzon O, Hirshberg B, et al. Changes in the lymphocyte count with saxagliptin and its association with clinical outcomes in the SAVOR trial [abstract no. 1209-P]. Diabetes. 2015;64(Suppl 1):A312.

    Google Scholar 

  56. US Food and Drug Administration. Kombiglyze XR (saxagliptin and metformin extended-release): US prescribing information. 2013. http://www.accessdata.fda.gov/. Accessed 26 Aug 2015.

  57. European Medicines Agency. Komboglyze (2.5 mg saxagliptin and 850 mg metformin): summary of product characteristics. 2015. http://www.ema.europa.eu/. Accessed 26 Aug 2015.

  58. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140–9.

    Article  PubMed  Google Scholar 

  59. American Diabetes Association. Glycemic targets. Diabetes Care. 2015;38(Suppl 1):S33–40.

    Article  Google Scholar 

  60. Handelsman Y, Bloomgarden ZT, Grunberger G, et al. American Association of Clinical Endocrinologists and American College of Endocrinology: clinical practice guidelines for developing a diabetes mellitus comprehensive care plan—2015. Endocr Pract. 2015;21(Suppl 1):1–87.

    Article  PubMed  Google Scholar 

  61. Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE/ACE comprehensive diabetes management algorithm 2015. Endocr Pract. 2015;21(4):438–47.

    Article  PubMed  Google Scholar 

  62. American Diabetes Association. Approaches to glycemic treatment. Diabetes Care. 2015;38(Suppl 1):S41–8.

    Article  Google Scholar 

  63. Rosenstock J, Gross JL, Aguilar-Salinas C, et al. Long-term 4-year safety of saxagliptin in drug-naive and metformin-treated patients with type 2 diabetes. Diabet Med. 2013;30(12):1472–6.

    Article  CAS  PubMed  Google Scholar 

  64. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–89.

    Article  CAS  PubMed  Google Scholar 

  65. Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care. 2009;32(1):187–92.

    Article  PubMed Central  PubMed  Google Scholar 

  66. Ryden L, Grant PJ, Anker SD, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J. 2013;34(39):3035–87.

    Article  PubMed  Google Scholar 

  67. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–72.

    Article  CAS  PubMed  Google Scholar 

  68. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129–39.

    Article  CAS  PubMed  Google Scholar 

  69. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–59.

    Article  CAS  PubMed  Google Scholar 

  70. Hayward RA, Reaven PD, Wiitala WL, et al. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;372(23):2197–206.

    Article  CAS  PubMed  Google Scholar 

  71. Frederich R, Alexander JH, Fiedorek FT, et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med. 2010;122(3):16–27.

    Article  PubMed  Google Scholar 

  72. Iqbal N, Parker A, Frederich R, et al. Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials. Cardiovasc Diabetol. 2014;13:33.

    Article  PubMed Central  PubMed  Google Scholar 

  73. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327–35.

    Article  CAS  PubMed  Google Scholar 

  74. Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232–42.

    Article  CAS  PubMed  Google Scholar 

  75. Monami M, Dicembrini I, Martelli D, et al. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin. 2011;27(Suppl 3):57–64.

    Article  CAS  PubMed  Google Scholar 

  76. Koska J, Sands M, Burciu C, et al. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes. Diab Vasc Dis Res. 2015;12(3):154–63.

    Article  CAS  PubMed  Google Scholar 

  77. Zannad F, Cannon CP, Cushman WC, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015;385(9982):2067–76.

    Article  CAS  PubMed  Google Scholar 

  78. Fu A, Johnston S, Ghannam A, et al. Risk of hospitalization for heart failure with dipeptidyl peptidase-4 inhibitors vs. sulfonylureas and with saxagliptin vs. sitagliptin in a U.S. claims database [abstract no. 164-LB plus poster]. In: 75th Scientific Sessions of the American Diabetes Association. 2015.

  79. Krum H, Skiba M, Wu S, et al. Heart failure and dipeptidyl peptidase-4 inhibitors. Eur J Heart Fail. 2014;16(6):603–7.

    Article  CAS  PubMed  Google Scholar 

  80. Goldenberg R, Ekoé J-M. A focus on CV safety in diabetes: highlights from ADA 2015. 2015. https://dxlink.ca/ADAReport/. Accessed 26 Aug 2015.

  81. Mosenzon O, Wei C, Davidson J, et al. Incidence of Fractures in Patients With Type 2 Diabetes in the SAVOR-TIMI 53 Trial. Diabetes Care. 2015. doi:10.2337/dc15-1068

Download references

Acknowledgments

During the peer review process, the manufacturer of saxagliptin was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand

    Sohita Dhillon

Authors
  1. Sohita Dhillon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sohita Dhillon.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

Sohita Dhillon is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.

Additional information

The manuscript was reviewed by: C. A. Aguilar-Salinas, Department of Endocrinology, Instituto Ncional de Ciencias Medicas Nutricion Salvador Zubiran, Mexico City, Mexico; D. S. Bell, Southside Endocrinology, University of Alabama Medical School, Birmingham, AL, USA; G. Dimitriadis, 2nd Department of Internal Medicine, Research Institute and Diabetes Center, Attikon Hospital, University of Athens, Greece; J. G. Eriksson, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; O. Mosenzon, Department of Medicine, Diabetes Unit, Hadassah Hebrew University Hospital, Jerusalem, Israel, I. Raz, Department of Medicine, Diabetes Unit, Hadassah Hebrew University Hospital, Jerusalem, Israel.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dhillon, S. Saxagliptin: A Review in Type 2 Diabetes. Drugs 75, 1783–1796 (2015). https://doi.org/10.1007/s40265-015-0473-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-015-0473-z

Keywords

Search

Navigation